Asklepios BioPharmaceutical, Inc.. Announces Cross License With GlaxoSmithKline

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asklepios Biopharmaceutical Inc. (“AskBio”), a private development-stage biotechnology company, has entered into a cross license agreement with GlaxoSmithKline (“GSK”) to develop and commercialize gene therapy based treatments. Through the agreement, AskBio will gain exclusive access to selected recombinant adeno-associated virus vector (“rAAV”) serotypes that GSK licensed from the University of Pennsylvania for the treatment of three orphan drug indications, including Muscular Dystrophy, heart failure suffered by Muscular Dystrophy patients, and Hemophilia B. Other terms of the agreement, including the technology licensed to GSK and the monetary terms related thereto, were not disclosed.